Article 107i referral: urgent Union procedure

An Article 107i referral, the urgent Union procedure, is a fast EU-level safety review when a medicine may need to be suspended, revoked or restricted.

Also known as: urgent Union procedure, Article 107i procedure

4 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Articles 107i to 107k of Directive 2001/83/EC
Started by
A Member State or the European Commission
Timeline
PRAC recommendation within 60 days, then CHMP or CMDh within 30 days
Applies to
Products authorised in more than one Member State, by any route

How it works

Articles 107i to 107k of Directive 2001/83/EC set out the urgent Union procedure. A Member State or the Commission must start it, on the basis of concerns from pharmacovigilance data, when it considers suspending or revoking a marketing authorisation, prohibiting the supply of a medicine or refusing a renewal. It must also start it when a holder tells it that, for safety reasons, the holder has interrupted marketing, has taken or intends to take action to have an authorisation withdrawn, or has not applied for renewal. Where a new contraindication, a reduction in the recommended dose or a restriction of the indications is considered necessary, the procedure is started if urgent action is needed.

Once the procedure is started, the European Medicines Agency checks whether the concern extends to other products, to the same range or to the whole therapeutic class, and sets the scope accordingly. If the product is authorised in only one Member State, that Member State deals with the concern itself. EMA announces the start publicly, naming the products and substances concerned, and invites holders, healthcare professionals and the public to submit information. The PRAC assesses the matter, with its rapporteur working with the CHMP rapporteur or the reference member state, and may hold a public hearing where the urgency allows.

The PRAC makes a recommendation within 60 days, or sooner in urgent cases. It can conclude that no action is needed, that holders should evaluate further data or sponsor a post-authorisation safety study, that risk minimisation measures are required, or that authorisations should be varied, suspended, revoked or not renewed. If no centrally authorised product is in scope, the CMDh adopts a position within 30 days: Member States implement a consensus position to the timetable it sets, and a majority position goes to the Commission for a decision. If a centrally authorised product is in scope, the CHMP adopts an opinion within 30 days and the Commission decides.

Interim action is possible. Under Article 107i(2) a Member State may suspend the authorisation and prohibit use of the product on its territory until a definitive decision is adopted, informing the Commission, EMA and the other Member States by the next working day, and the Commission can ask Member States to take temporary measures at any stage. The procedure differs from the Article 31 referral, which has no urgency requirement and a longer timetable, and from Article 20 of Regulation (EC) No 726/2004, which covers only centrally authorised products.

What goes wrong

A holder withdraws a product or lets a renewal lapse for safety reasons without realising that the notification itself can start the procedure for every product with the same substance; holders of generics miss the public announcement and the window to submit data; responses are thin because the timetable leaves weeks, not months; and the implementation deadline in the CMDh position or Commission decision arrives before variations, artwork and any direct healthcare professional communication are ready.

Timing

  1. Start

    A Member State or the Commission notifies the concern; EMA sets the scope and announces the procedure.

  2. Data window

    Holders, healthcare professionals and the public may submit information; a public hearing is possible.

  3. Within 60 days

    PRAC adopts its recommendation.

  4. Within 30 days

    CMDh position, or CHMP opinion where a centrally authorised product is in scope.

  5. Implementation

    Member States act on a consensus position, or the Commission adopts a decision.

The procedure starts when the Member State or the Commission informs the other Member States, EMA and the Commission, and EMA announces it publicly. The PRAC makes its recommendation within 60 days of the information being submitted, or sooner on a proposal from its chair. The CMDh or the CHMP then has 30 days from receipt of the recommendation. A consensus CMDh position is implemented to the timetable it contains, with holders submitting variations within that timetable; otherwise the Commission adopts a decision under Articles 33 and 34.

Article 107i referral: common questions

What is the difference between an Article 107i and an Article 31 referral?

Both can review a safety concern across a substance or class. Article 107i is for cases where urgent action is considered, such as suspension, revocation or a ban on supply, and runs to fixed limits of 60 days for the PRAC and 30 days for the CHMP or CMDh. Article 31 has no urgency requirement, can also cover non-safety questions and allows a longer assessment with clock-stops.

Who can start an urgent Union procedure?

Only a Member State or the European Commission. A marketing authorisation holder cannot start one, but its own actions can lead to one: when a holder notifies a Member State that it is withdrawing a product, interrupting supply or not renewing an authorisation for safety reasons, the Member State must start the procedure.

Can a Member State act before the procedure ends?

Yes. Where urgent action is necessary to protect public health, a Member State may suspend the marketing authorisation and prohibit use of the medicine on its territory until a definitive decision is adopted. It must inform the Commission, EMA and the other Member States of its reasons no later than the following working day.

Sources

  1. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use, consolidated text
  2. European Medicines Agency: Referral procedures for human medicines

Put your Article 107i referral question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.